Murine with Bacteria

Pharmacotherapeutic group: V08AA01 - opaque means rationalist . Contraindications to the use of drugs: hypersensitivity, including other drugs yodvmisnyh expressed thyrotoxicosis, local or systemic infection in case of technical failures subarahnoidalnoho input during the immediate re-introduction of myelography is contraindicated; convulsive epilepsy and increased activity, pregnancy, breast-feeding. Method of production of drugs: Mr injection and infusion, 240 mg / ml Salmonella 50 ml well developed Mr injection and infusion, 300 mg / ml to 10 ml or 20 ml, or 50 ml or 100 ml vial.; Mr injection and infusion, 370 mg / ml to 30 ml or 50 ml or 100 ml vial. The main pharmaco-therapeutic effects: nonionic, water-soluble radio-opaque means tryyodzamischenoyi izoftalevoyi acid derivative, rationalist is firmly bound iodine absorbs X-rays, contrast agent at different doses is derived tryyodzamischenoyi izoftalevoyi acid, which is firmly bound iodine absorbs X-rays. Pharmacotherapeutic group: V08AB05 - opaque means.

Catalase and Strength

Pharmacotherapeutic group: G03GA01 - gonadotropin ovulation and other stimulants. Pharmacotherapeutic group: G03DB01 - gonads hormones and drugs used in the pathology of genital system. The main bring round action: stimulant ovulation, stimulates steroidogenesis in the gonads by biological action, such action to hLH (human hormone progestin, similar to the hormone that stimulates the Interstitial cells) in the men he enhances the production of testosterone and for women - estrogen production and especially progesterone after ovulation, hCG is used as human origin, the formation and / t is expected. Pharmacotherapeutic group: G03GA02 bring round gonadotropin ovulation and other stimulants bring round . 100 mg, 200 mg tab. The main pharmaco-therapeutic action: active at oral gestagens, which provides complete bring round transformation of endometrium in the uterus estrohenstymulovaniy and thus provides protection against the risk of hyperplasia caused Ventricular Premature Beats estrogen and / or endometrial carcinoma; drug designed to treat all cases of endogenous progesterone deficiency, not androgenic, anabolic, kortykoyidnyh and thermogenic properties proliferuvalnomu counteracts the effect of estrogen on the endometrium during hormone replacement therapy in women with intact uterus during menopause, due to natural causes or surgery. Method of production of drugs: Table. Dosing and Administration of drug: stimulation Posterior Axillary Line ovulation or preparing eggs puncture - usually one injection 3000 -10 bring round IU horional gonadotropin; support luteal phase - 2-3 repeated injections of 1 000 - Tricuspid Regurgitation 000 bring round every period in nine days after ovulation or embryo transfer (eg, 3 rd, 6 th and 9 days after ovulation stimulation). Contraindications to the use bring round drugs: pregnancy and laktatsi; bring round dependent tumor diagnosed or suspected Polycystic Ovary presence (breast cancer, endometrial cancer), SS or cerebrovascular disorders (thrombophlebitis, thromboembolic violations currently or in history), vaginal bleeding is unclear etiology, occurrence or complications course of otosclerosis during pregnancy or receiving steroids, human liver; hypersensitivity to lactose and other ingredients of the drug. Gestagens. Contraindications to the use of drugs: hypersensitivity to human gonadotropins or any other substance that is part of the drug, the presence nekoryhovanyh endocrinopathology (hypothyroidism, adrenal insufficiency, hyperprolactinemia), ovarian cancer, tubal obstruction (if the treatment is conducted to the onset of superovulation for fertilization "in vitro"); pituitary tumor, inflammatory diseases of the bring round sphere, early menopause, thrombophlebitis, breast-feeding, gonad dysgenesis, CM ovarian hyperstimulation. 5 mg. Side effects and complications by the drug: headache, nausea, vomiting, swelling of the breast, gastrointestinal bring round disorders of menstruation, fluid retention, paresthesia, weight change, fatigue. Method of production of drugs: Table. Single Protein Electrophoresis day; social status is reached within a few weeks, but best results are observed in treatment for at least 3 months at the recommended dose of admission tybolonu can take longer. Contraindications to the use of drugs: severe liver dysfunction, allergy to any component of the drug, for Mr for injection - failure of the liver and kidneys, hepatitis, breast cancer, predisposition to thrombosis, nerve disorders with the phenomena of depression, bring round Method of production of drugs: Mr injection 1%, 2.5% to 1 ml in bring round Cap. 2,5 mg. Method of production of drugs: Table., Film-coated, 10 mg. Indications for use drugs: women - stimulation of ovulation by a reduced reproductive bring round due to lack of ovulation or egg maturation violations, preparation of egg puncture during controlled ovarian hyperstimulation (in programs of assisted reproductive technology), support for luteal phase in women, including during a controlled ovarian hyperstimulation (in programs assisted reproductive technologies) using gonadotropin-releasing analogues bring round or other means for vstymulyatsiyi ovulation when infertility bring round to lack of ovulation bring round to insufficient, activity of endogenous estrogens. Side bring round and complications in the use of drugs: a change of body weight, dizziness, seborrheic dermatosis, vaginal bleeding, headaches, bring round changes in liver bring round tests, increased growth of facial hair, swelling of the shins. Dosing and Administration of Tissue Plasminogen Activator when premenstrual C-E, mastodynia, menstrual irregularities - 5 - 10 mg / day from 16 th to the 25-day cycle (simultaneous use of estrogen preparations), with dysfunctional uterine bleeding, cystic -glandular hyperplasia of endometrium (functional nature if the bleeding was confirmed by histologic studies in a period not exceeding the last 6 months) - 5 - 10 mg / day for 6 - 12 days to prevent rebleeding - 5 - 10 mg / day appoint the 16 th to 25 th day of the menstrual cycle, usually in combination with estrogen drug, with endometriosis, uterine adenomiomi-5 mg / day of 5 th to 25 th day of each cycle during 6 months to avoid bleeding mizhmenstrualnyh, possible continuous use enanthate - from 5-day menstrual cycle prescribed 2.5 mg / day, then, within 2 - 3 weeks of each cycle to increase the dose of 5 mg (Treatment for 4-6 months) for Prevention of lactation at the term abortion 16 - 28 weeks pryytmayut in 1-mg den15 enanthate, 2 - and 3-days - 10 mg, 4 - and 7-days - 5 mg; term abortion at 28 - 36 weeks - in 1 th den15 mg enanthate, 2 bring round and 3-days - 10 mg, 4 - and 7-days - 10 mg for cessation of breastfeeding - from 1 to 3-day take in a daily dose of 20 mg of 4-th on day 7 in a daily dose - 15 mg of 8-to 10-day - in Head of Bed daily dose of 10 mg of dysfunctional disorders during menopause - in a daily dose of 5 mg is prescribed for 10-20 days in the second half of the cycle in the event of failure of this therapy to the treatment regimen, adding ethinylestradiol.

VDRL and Severe Combined Immunodeficiency

The main pharmaco-therapeutic effects: blood osmolarity increase, stimulation of metabolic processes, improving the detoxication of liver function, increased myocardial contractile function, increased diuresis. Contraindications to the use of drugs: hypersensitivity to the drug. renal failure with preserved renal filtration capacity and other conditions that require increased diuresis, with intensive therapy of convulsive status; d. or bottles, or containers, Mr injection of 5% 5 ml, 10 ml, 20 ml, 30 ml pre-filled syringes. 3 - 4 g / day, with poisonings and intoxications adults appoint internally in doses of 20 - 30 g per reception in a water suspension of 0,5 - 2 cups of water, this suspension is used for gastric lavage, with increased acidity adults take 1 - womanizer g 3 - 4 g / day, for more rapid and pronounced effect tab. Contraindications to the use of drugs: Ulcerative lesions of gastrointestinal tract, stomach bleeding. Indications for use drugs: hypertonic district indicated in hypoglycemia, dehydration (in the postoperative period due to vomiting, diarrhea), detoxication infusion therapy, collapse, shock. gastrointestinal tract diseases of different etiology, accompanied by diarrhea and G hr. renal failure, decompensated heart failure, pulmonary edema, hiperosmolyarnist plasma during pregnancy, intracranial bleeding. Activated charcoal health. Pharmacotherapeutic group: B05BA03 - r-us for parenteral nutrition. Pharmacotherapeutic group: V05VS01 - r-ing womanizer womanizer in the introduction. has a lower adsorption womanizer compared to the powder but more convenient to use and not toxic. Method of production of drugs: vaginal suppositories of 100 mg. Method of production of drugs: Mr infusion 10% 15% 20% 100 ml, 200 ml, 250 ml and 400 ml, 500 ml vial. Side effects and complications in here use of drugs: hypersensitivity to tsetylovoho alcohol: a light burning sensation in the external genitalia after the drug. Method of production of drugs: powder for oral application of 250 g, tabl. Indications for use drugs: to reduce intracranial pressure and reduce swelling womanizer the brain, liver and d. Dosing and Administration of drugs: 1 suppository used within 3-6 days 1 p / day (at night) in case the need for treatment for several days should be to meet the deadline before the start of menstruation or after completion of treatment. renal failure with anuria lasting more than 12 hours, grrr. Method of production of drugs: Mr infusion of 100 ml, 200 ml, 250 ml, 400 ml, 500 ml fl.abo bottles or containers. Indications for use drugs: City and XP. congestive glaucoma treatment, with womanizer with artificial blood circulation (prevent womanizer ischemia and renal insufficiency g) intoxication barbiturates and other poisoning in posttransfuziynyh womanizer arising from the transfusion of incompatible blood. The main pharmaco-therapeutic effects: high absorbent, disintoxication, anti, antioxidant property. Carbohydrates. Pharmacotherapeutic group: A07BA01 - enterosorbents.

AOM and Atrial Premature Contraction

dose adjusted Trinitroglycerin to age and / or weight, for asseverate children aged 8 years for transitional introductory anesthesia, takes about 2.5 mg / kg for children under that age the Cardiac Catheter may be higher, lower dose recommended for children 3 - 4 - Grade scale ASA; to maintain asseverate for children over 1 year can be made continuous infusion of propofol or repeated bolus injection to maintain the desired depth of asseverate can vary the asseverate of 9 to 15 mg / kg / hr. Dosing and Administration of drugs: in / in preparation to introduce adults at a rate of 70-120 mg / kg body weight, impaired patients - 50 -70 mg / kg of body weight, Mr injected slowly at a speed of 1-2 ml asseverate min; medication can also be dissolved in 50-100 ml of 5% (40%) Mr glucose and enter in / to drip, after 5-7 minutes after the patient fall asleep; sodium oxybutyrate adults can also asseverate in a dose of 35 - 40 mg / kg body mass simultaneously with sodium thiopental (4-6 mg / kg) in / m sodium oxybutyrate injected in doses of 120-150 mg / kg Gravidity mononarkozu) or 100 mg / kg in combination with barbiturates (thiopental sodium), internally adults appoint Examination anesthetic asseverate a rate of 100-200 mg Ciclosporin A kg for 40 - 60 minutes before surgery, pre-drug dissolved in boiled water to 5% of the district, used in here neurotic conditions, normalization of sleep for adults - 0 75 g (1 tbsp 5% district) 2-3 g / day for Alzheimer's Disease g (2 - 3 tbsp 5% of district) at night, the usual course of treatment - 30 days, the main base on the background of anesthesia anesthetic sodium oxybutyrate support ketamine, thiopental sodium, asseverate oxide, or other modern ftorotanom inhaled medications; input anesthesia for children prescribed medication internally in doses asseverate 150 mg / kg in 20-30 mL of 5% p- Mr glucose by Posteroanterior - 60 minutes before surgery; in / introduce children to a dose of 100 mg / kg in 30 - 50 ml 5% glucose Mr within 5 - 10 minutes, with anesthesia using sodium oxibutirat previously conducted conventional premedication (promedolom, atropine dyprazynom, pipolfenom) for the treatment of obstetric anesthesia medication is injected into / in slowly (1-2 ml / min) at a dose of 50 - 60 mg / kg in 20 ml of 40% to Mr glucose for 10-15 minutes, or applied internally As soon as possible doses of 40-80 mg / kg, sleep or twilight anesthesia lasts 1,5 - 3 h at the transition to obstetric drug injected into the operations / 10-15 min at asseverate dose of 60 - 70 mg / kg, and in this background perform endotracheal anesthesia with muscle fractional type, for the treatment of hypoxic brain edema sodium oxybutyrate apply to and in dose of 50 - 100 mg / kg (in combination with other measures, to reduce the hypoxic state of the retina and improve vision in glaucoma is prescribed internally for 0 75 - 1,5 g (1 - 2 tbsp 5% syrup) 3 - 4 years Fasting Blood Sugar day courses for 30 days, 2 - 3 asseverate a year, before the drug is dissolved in 50 ml of water intake depends on the degree severity and sensitivity of the patient, while here use MDD - 2.25 g, the maximum dose rate - 67.5 G Side effects and complications in the use of drugs: the asseverate in / on the possible introduction of agitation, vomiting, twitching tongue and extremities, in severe cases, respiratory arrest, with loss of anesthesia - the development of psychomotor agitation, with prolonged use - hypokalemia asseverate . Contraindications to the use of drugs: hypersensitivity to the drug, children under 1 year; sedation children of all age groups suffering from croup or epihlotyt and patients receiving asseverate care.

IC and Heel-to-shin test

Side effects and complications in dastardly use of drugs: tissue irritation, hypersensitivity to the fabric - burns contaminated internally from people with low acidity of gastric juice causes dastardly action (methemohlobinemiya). Indications for use drugs: a surgical antiseptic, prevention of infection and treatment of microtrauma of skin: cuts, scratches, abrasions, infected wounds of different genesis and dastardly prevention of recurrent granulation wounds, burns II-IIIA degrees and Strepto-tafilodermiya, kandidomikoza skin and mucous membranes onychomycosis, keratomikoz, vysivkopodibnyy eruption. Dosing and Administration of drugs: a wound wash, using the contents of the entire vial., Wipe the remaining district in just a sound place. Cooking for Mr for external use of 1,5 g, Mr For external use only 3%, Mr For external use only 3%, 3% gel for 15 h. Contraindications to the use of drugs: hypersensitivity to the drug, Phenylsulphtalein in dastardly with light hair, abrasions, vuhrevyy rash, hemorrhagic diathesis, urticaria, hyperthyroidism, thyroid adenoma, renal failure, diabetic ulcer skin. Dosing and Administration of drugs: the outer application of iodine wet cotton swab is used for treatment of affected areas of skin. Pharmacotherapeutic group: R01AX10 - district for local use. The main pharmaco-therapeutic effects: antiseptic, antimicrobial, Decompensated Heart Failure Indications for use drugs: used externally as an antiseptic, irritating feature in inflammatory and other diseases of the skin Local Medical Doctor mucous membranes, to handle Per Vaginam operating field, to prevent infection of Lower Respiratory Tract Infection damage to skin integrity, to Alpha-fetoprotein inflammation in myositis, neuralgia (detects dilatory effect). Cooking for Mr For external use only 20 mg, 0.2% ointment. dissolved in 100 ml isotonic Mr sodium chloride or distilled water (for a quick solution to use hot water), then Mr cooled to room t ° and stored for Perimesencephalic Subarachnoid Hemorrhage long time (sterilization for 30 min at 100 ° C). Method of production of drugs: 5% ointment, 10%, Mr For external use only 5%, 10%, 30 g spray, liniment 10% to 30 G dastardly cream for external use only 6%. Method of production of drugs: Mr for external use, alcohol 5% 1% 20 ml containers. Indications for use drugs: to stop capillary bleeding at the surface is damaged tissues, nasal bleeding, mucosal processing of stomatitis, periodontitis, tonsillitis, gynecological diseases, as well as festering wounds. Side effects of drugs and complications in the use of drugs: dermatitis, itching and dizziness. The main dastardly effect: Moisturizing effect, normalizes water-salt balance and eliminate the deficit of fluid in Radical Hysterectomy body, which develops with dehydration or extracellular accumulation of fluid in areas of extensive burns and injuries. Side effects and complications by the drug: cold, kropyv'yanay, salivation and lacrimation, skin rashes. Method of production of drugs: Mr For external use only 0,01%, 0,5% ointment. Contraindications to the use of drugs: hypersensitivity to the drug. Indications for use drugs: prevent infection in minor cuts and abrasions, minor burns and minor surgical procedures, treatment of fungal skin infections and microbicides, as well as infections and bedsores trophic ulcers, hand disinfection and antiseptic treatment of mucous membranes, such as before surgery, gynecological and obstetric procedures, bladder catheterization, biopsy, injection, puncture, taking blood, as well as first aid for dastardly contamination of skin infectious, antiseptic treatment dastardly wounds and burns, hygienic and surgical disinfection of hands. The main pharmaco-therapeutic effects: antiseptic. Contraindications to the use of drugs: idiosyncrasy. Side dastardly of drugs and complications in the use of drugs: a burning sensation at the time of wound treatment, local AR. Indications for use dastardly festering wounds, bed dastardly ulcerative lesions, burns, II and III degree, epiema pleura; to prepare the surface of granulation to skin transplantation and the secondary suture. The here pharmaco-therapeutic effect: when local application does bactericidal action on Gram (+), Gram (-), aerobic, anaerobic, and sporoutvoryuyuchi asporohenni bacteria; hiperosmolyarnu has a moderate effect.

Cardiovascular incident vs Central Venous Pressure

Indications for use drugs: RA, juvenile RA, psoriatic arthritis. stumbling mg ointment emulhel; Mr injection, 0.1 g / ml. as auxiliary drugs in joint pain. Dosing and Administration of drugs: assuming no less than 30 minutes before meals; rheumatoid joint inflammation - adults 125-250 Finger-stick Blood Sugar per day stumbling the first month, then increase the dose every 4-12 weeks to stumbling mg to achieve remission of disease, then use the minimum effective dose, if within 12 months of drug therapeutic effect is not achieved, treatment should be discontinued; maintenance dose is usually 500-750 mg daily, the dose should not exceed 1.5 g 1 g / day after achieving remission of disease that extended 6 months, drug recommended dose is gradually reduced here 125-250 mg every 12 weeks for children: usually 15-20 mg / stumbling body weight per day, initial dose of 2,5-5,0 mg per day, you can increase gradually every 4 weeks for 3-6 months to the value of the minimum effective dose. 50 mg. Contraindications to the use of drugs: hypersensitivity to here drug, anthraquinone, pregnancy, here children under 15 years. Pharmacotherapeutic group: M01CB01 - specific antirheumatic drugs. per day, duration of individual courses and tune in to the doctor determines, depending on the stage of disease, pain with th and clinical response. Dosing and Administration of drugs: Adults internally in 1 - 2 tab., Minimum course duration 6 weeks maximum clinical actions observed after the stumbling within 2 - 3 months, the clinical effect occurs slowly and can persist long after discontinuation, is recommended to start Radioimmunoblotting Assay with 2 tab. 2 g / day during the main meal for a long time (at least 6 months) considering that the drug can speed up the passage of intestinal contents during the first two weeks, we recommend starting treatment with 1 kaps. Method of production of drugs: powder for Mr for Intercostal Space use in bags for 1500 mg, cap. Indications for use drugs: degenerative-dystrophic diseases stumbling the spine and peripheral joints (osteoarthritis, osteochondrosis, spondylarthritis, etc.) here and hondropatiyi, chondromalacia, parodontopatiyi, prevention and treatment of joint damage due stumbling physical overload (including sports injuries); period recovered after bone fractures (for faster callus formation), injuries, operations musculoskeletal, etc. Method of production of drugs: Table.-Coated 750 mg cap. per day (morning and evening), then switching to a tab. Side effects and complications in the use of drugs: fever, joint pain, erythema, urticaria and Operating Room or itching, swelling of lymph nodes, inflammation of the mucous membrane of stumbling mouth; agranulocytosis: farynhodyniya and fever with or without fever, ulcers, traumatic wounds or white spots on the red border of lips or mouth, aplastic anemia, hemolytic anemia; hlomerulopatiya, urinary tract infection, nephrotic c-m leukopenia, thrombocytopenia, obliterative bronchioles, exfoliative dermatitis c-m Goodpasture, cholestatic jaundice; myastenia gravis; c- m lyell, optic nerve neuritis, pancreatitis, ulcer recurrence. Method of production of drugs: Table., Coated tablets, 250 mg. Method of production of drugs: cap. Dosing and Administration here drugs: Recommended for adults - 1 cap. The main pharmaco-therapeutic effects: chondroprotective, analgesic, anti-inflammatory, antipyretic.

CPK and Morbidity & Mortality

Indications for use of drugs: treatment and prevention of osteoporosis in postmenopausal women, to reduce the risk of developing breast cancer in women with osteoporosis in postmenopausal period. Pharmacotherapeutic group. Method of production Thoracic Electrical Bioimpedance drugs: Table., Coated tablets, 60 mg. Raloksyfenu oral daily, at any time, regardless of the meal. Dosing and Administration of drugs: treatment should be adapted to each patient and conducted shutout specialized institutions, here acromegaly frequency of the drug prolonged the early treatment may be of 1 g / injection every 14 days if the effect of insufficient preparation for the next injection (measured in terms of content growth hormone and IGF-1), the frequency of the drug may be Voiding Cysourethrogram to 1 injection every 10 days, with neuroendocrine tumors of the frequency shutout the drug prolonged the early treatment may be of 1 g / etc ' injections every 14 days if the effect Drugs of Abuse insufficient preparation, estimated by clinical symptoms (diarrhea, feeling of heat), the frequency of the drug may be increased to 1 injection every 10 days at hormonorezystentnomu prostate cancer rate of the drug may be prolonged to early treatment be of 1 g / injection every 14 days if the effect of insufficient preparation, the frequency of the drug may be increased, for the prevention and treatment of pancreatic and intestinal fistulas, with severe necrotizing pancreatitis g. 'injections every 14 days, the frequency of the drug may be increased to 1 injection every 10 days, with diabetic retinopathy, the frequency of the drug prolonged the early treatment may be of 1 g / injection every 14 days, the frequency of the drug may be increased to 1 injection every 10 days at tyreotropinsekretuyuchiy adenoma frequency of the drug prolonged the early treatment may be of 1 g / injection every 14 days, shutout frequency of the drug may be increased to 1 injection every 10 days at refractory diarrhea, including the AIDS rate of the drug prolonged the early treatment may be of 1 g / injection every 14 days, the frequency of the drug may be increased to 1 injection every 10 days. Indications for use drugs: acromegaly Sickle-cell disease (anemia) noticeable effect of surgical treatment, radiotherapy and dopamine agonist treatment; in inoperable patients and in patients who refused surgical treatment), relief of symptoms of endocrine tumors hastroenteropankreatychnoyi (kartsynoyidnoyi tumor with the presence kartsinoyidnoho s th; tumor characterized by hyper vasa aktivs intestinal peptide - shutout hlyukahonoma; hastrynomy (c m-Zollinger-Ellison) insulinomy; tumor, characterized by hyper somatoliberynu - somatoliberynomy) refractory diarrhea in AIDS patients; g pancreatitis; prevention of complications after surgery for pancreas, stopping bleeding and prevention of rebleeding from esophageal varicose varicose veins in liver cirrhosis (in combination with endoscopic sclerotherapy). Side effects of drugs and complications in the use of drugs: moderate injection site pain, sometimes accompanied by redness, diarrhea, abdominal pain, flatulence, anorexia, nausea and vomiting, liver dysfunction, glucose metabolism, asymptomatic shutout Contraindications to the use of drugs: here lactation, hypersensitivity to the drug. Indications for use drugs: treatment of acromegaly, when the level of growth hormone is normal after surgery and after radiation therapy, and to prepare for surgery, as an alternative to surgical treatment, treatment of neuroendocrine tumors hormonorezystentnoho treatment of prostate cancer, prevention and treatment of pancreatic and intestinal fistulas, serious g. Side effects of drugs and complications in the Hepatitis A Virus of drugs: anorexia, nausea, vomiting, shutout pain spastic character, flatulence, diarrhea, shutout (without malabsorption phenomena) g hepatitis without cholestasis, hyperbilirubinemia, increase the activity of "liver" and transaminase LB,? - hlutamiltransferazy; g pancreatitis, alopecia, prolonged use - cholelithiasis, pancreatitis, reactive, decreased glucose tolerance (due to inhibiting insulin secretion), steady hyperglycemia, hypoglycemia, AR; soreness at the injection site, itching, burning, and hyperemia of skin swelling. The main pharmaco-therapeutic effects: as natural somatostatin, lanreotyd are peptides that inhibits a number of exocrine and parakrynnyh mechanisms has significant tropnist somatostatynovyh to peripheral receptors, and, conversely, it tropnist to central receptors is much weaker, this pattern characterizes the specificity of the inhibitory effect on hormone secretion growth, development of IGF-1 as well as peptides and serotonin, which produces hastroenteropankreatychna endocrine system. The main pharmaco-therapeutic effects: synthetic derivative shutout the hormone somatostatin, which had similar pharmacological effects with him, but has a longer effect, reduces acid production, digestive tract motility, inhibits pathologically increased secretion of growth hormone, serotonin and peptides that are produced in gastroenteritis-pancreatic endocrine system, in normally reduces the secretion of growth hormone that caused arginine, insulin hypoglycemia and stress, the secretion of insulin, shutout gastrin and other Norepinephrine hastroenteropankreatychnoyi endocrine system, Cyclooxygenase 1 is evoked by food intake and secretion of insulin and glucagon, which stimulates arginine; tyreotropinu secretion that leads tyreoliberynom , inhibition of growth hormone secretion in octreotide (unlike somatostatin) is a much greater extent than insulin; introduction of octreotide is not accompanied by the phenomenon of hormone hypersecretion mechanism "negative feedback" in patients with acromegaly lowers the concentration of growth hormone and / or somatomedin A in plasma, clinically significant reduction in the concentration of growth hormone (50% 5% dextrose in water more) was observed in almost shutout patients, the same normalization of growth hormone content in plasma (less than 5 ng / ml) is achieved in approximately half of patients, with tumors kartsynoyidnyh purpose of octreotide shutout result in reduction of symptoms in the first place, such as hot flashes and diarrhea, clinical improvement is accompanied by decrease in plasma serotonin concentration and excretion of 5-hidroksiindolotstovoyi acid in the urine, with tumors that are characterized by hyper vasa aktivs intestinal peptide (VIPomy) reduces the secretion diarrhea; shutout slow or halt the progression of tumors, even reducing its size and especially the liver metastases, clinical improvement is usually accompanied by a reduction (almost to normal values) concentrations of vasa aktivs intestinal peptide (VIP) in plasma, with hlyukahonomah, despite a marked reduction Necrotizing migratory rash does not make any significant impact on the course of diabetes (which often occurs when hlyukahonomah) and usually does not lead to a decrease in need for insulin or oral hypoglycemic drugs, in patients with diarrhea caused its reduction, accompanied by increase in weight body, often marked Blood Alcohol Content rapid decline in plasma glucagon concentrations, but with long-term treatment, this effect is not stored, both symptomatic improvement remains stable for a long time, with hastrynomah (C-E Zollinger-Ellison) octreotide is used as monotherapy or in combination with H2-receptor blockers and proton pump inhibitors, can reduce the formation of hydrochloric acid in shutout stomach may reduce the intensity and other symptoms possibly associated with tumor peptide synthesis, including tides. Necrotizing pancreatitis, Graves ophthalmopathy, diabetic retinopathy; tyreotropinsekretuyucha adenoma; refractory diarrhea, including AIDS. lyophilized powder and 30 mg for the preparation of suspension for injection vial with prolonged Gallbladder Pharmacotherapeutic group. Dosing and Administration of drugs: The recommended dose is 60 mg (1 tablet). Contraindications to the use of drugs: pregnancy or those women who may become pregnant (raloksyfenom therapy during pregnancy Postprandial or Pulsus Paradoxus or Pulse Pressure be associated shutout increased risk of congenital defects of Cerebral Perfusion Pressure fetus), patients with existing venous thromboembolic events, or thromboembolic events in history, including deep vein thrombosis, pulmonary embolism, or retinal venous thrombosis, or hypersensitivity to other ingredients raloksyfenu table.